Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.71 |
| ▸ | IDO1 | P14902 | 2/20 | 0.62 |
| ▸ | AGXT | P21549 | 2/20 | 0.62 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264 | 0.92 | IDO1 (0.71) | MAOBIDO1AGXTABCB1HTR1A | |
| SCHEMBL10820376 | 0.91 | MAOB (0.67) | MAOBMRGPRX4APPNPC1RAB9A | |
| SCHEMBL2094987 | 0.89 | MAOB (0.71) | MAOBBCHE | |
| SCHEMBL13462942 | 0.87 | MAOB (0.69) | MAOBIDO1AGXTMRGPRX4APP | |
| SCHEMBL13263642 | 0.87 | MAOB (0.79) | MAOBIDO1AGXTMRGPRX4RAB9A | |
| SCHEMBL14547318 | 0.87 | MAOB (0.81) | MAOBIDO1AGXTMRGPRX4NPC1 | |
| SCHEMBL13144444 | 0.86 | MAOB (0.87) | MAOBIDO1AGXTMRGPRX4APP | |
| SCHEMBL16710548 | 0.86 | MAOB (0.76) | MAOBIDO1ACHE | |
| SCHEMBL4697138 | 0.86 | MAOB (0.67) | MAOBIDO1AGXTMRGPRX4APP | |
| SCHEMBL810700 | 0.84 | MAOB (0.70) | MAOBIDO1AGXTMRGPRX4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | UNIVERSITE DE MONTREAL (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133446-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | MAOB 2077/4885IDO1 1025/4885AGXT 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.